Literature DB >> 831730

Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.

R K Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 831730     DOI： 10.1016/0006-2952(77)90137-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  10 in total

1.  Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).

Authors:  G J Peters; S L Sharma; E Laurensse; H M Pinedo
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

2.  Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors.

Authors:  A Zeevi; G Z Yao; R Venkataramanan; R J Duquesnoy; S Todo; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

3.  A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.

Authors:  E S Casper; J Baselga; T B Smart; G B Magill; M Markman; A Ranhosky
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Comparison of the bioavailability of uridine in mice after either oral or parenteral administration.

Authors:  P Klubes; D B Geffen; R L Cysyk
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.

Authors:  M Markman; T C Chan; S Cleary; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Uridine rescue from the lethal toxicity of 5-fluorouracil in mice.

Authors:  P Klubes; I Cerna; M A Meldon
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis.

Authors:  K Bhalla; S Grant
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 8.  m-AMSA and PALA: two new agents in cancer chemotherapy.

Authors:  M Rozencweig; D D Von Hoff; R L Cysyk; F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

9.  Uridine pharmacokinetics in cancer patients.

Authors:  T C Chan; M Markman; C E Pfeifle; R Taetle; I Abramson; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 10.  Nucleoside salvage and resistance to antimetabolite anticancer agents.

Authors:  M Fox; J M Boyle; A R Kinsella
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.